Stockreport

Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma

Actuate Therapeutics, Inc. - Common stock  (ACTU) 
PDF Ewing Sarcoma is a Highly Metastatic Form of Sarcoma and the Second Most Prevalent Primary Malignant Tumor in Children and AdolescentsOngoing Enrollment in Phase 1/2 T [Read more]